AJHE2315 - CME/CMLE - One-year retrospective analysis of anti-FXa apixaban and rivaroxaban levels demonstrates utility for management decisions in various urgent and nonurgent clinical situations-One-year retrospective analysis of anti-FXa apixaban and rivaroxaban levels demonstrates utility for management decisions in various urgent and nonurgent clinical situations

One-year retrospective analysis of anti-FXa apixaban and rivaroxaban levels demonstrates utility for management decisions in various urgent and nonurgent clinical situations

Back to course

Pdf Summary

The document explores the significance of utilizing apixaban and rivaroxaban anti-FXa assays in clinical settings to guide decision-making in urgent and nonurgent scenarios over a one-year period. These tests prove valuable in informing reversal strategies, timing surgical procedures, and managing patients on direct oral anticoagulants. The study emphasizes the importance of measuring DOAC plasma levels for clinical decisions beyond existing testing guidelines, particularly in acute bleeding cases. Clinical context often influences decisions regarding andexanet reversal, and patients with bleeding tendencies may be managed without reversal agents. The integration of machine learning models assists in predicting clinical actions based on patient and clinical characteristics, revealing hidden influences on decision-making. The research highlights the importance of DOAC testing in diverse clinical situations and advocates for widespread adoption of these assays to enhance decision-making and patient outcomes. The study underscores the impact of DOAC testing in managing various medical scenarios effectively, suggesting that laboratory-guided decision-making with these assays can improve patient outcomes and cost-effectiveness in healthcare systems.

Keywords

apixaban

rivaroxaban

anti-FXa assays

clinical settings

decision-making

urgent scenarios

nonurgent scenarios

reversal strategies

direct oral anticoagulants

DOAC plasma levels